C

    CG Oncology, Inc. Common stock (CGON)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $75.16
    +0.82 (+1.10%)

    Market Cap: $6.66B

    Last updated: Sep 01, 2026 at 4:59 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    27%(3/11)
    Avg Surprise
    -15.70%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.81
    Range$-0.96 - $-0.66
    12 analysts
    EPS RevisionsNo revisions (7d)
    0
    5
    30d
    EPS Estimate Drift
    90d ago$-0.67+17.6%
    60d ago$-0.67+17.6%
    30d ago$-0.67+17.6%
    7d ago$-0.82-0.7%
    Current$-0.81
    Revenue Consensus
    $534480
    Range$0 - $1M
    12 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.21
    Range$-1.61 - $-0.80
    13 analysts
    Revenue Consensus
    $3M
    Range$849850 - $17M
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.21---
    Sep 26EST
    		-$-0.81---
    Jun 26
    Reported Aug 6
    		$-0.90$-0.70-28.57%Miss-66.7%
    Mar 26
    Reported May 8
    		$-0.71$-0.58-22.41%Miss-57.8%
    Dec 25
    Reported Feb 27
    		$-0.51$-0.48-6.25%Miss-10.9%
    Sep 25
    Reported Nov 14
    		$-0.57$-0.55-3.64%Miss-90.0%
    Jun 25
    Reported Aug 8
    		$-0.54$-0.45-20.00%Miss-92.9%
    Mar 25
    Reported May 13
    		$-0.45$-0.37-21.62%Miss-25.0%
    Dec 24
    Reported Mar 28
    		$-0.46$-0.45-2.22%Miss-39.0%
    Sep 24
    Reported Nov 14
    		$-0.30$-0.34+11.76%Beat-
    Jun 24
    Reported Aug 8
    		$-0.28$-0.31+9.68%Beat-
    Mar 24
    Reported May 9
    		$-0.36$-0.15-140.00%Miss-
    Dec 23
    Reported Mar 26
    		$-0.33N/A+50.61%Beat-

    Key Metrics

    Valuation
    P/E Ratio-27.94EV/EBITDAN/A
    Price/FCF-36.96xFCF Yield-2.71%
    Profitability
    Profit Margin0.00%Operating Margin-7468.00%
    ROE-26.40%ROIC-19.35%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio22.22xQuick Ratio22.20x
    Trading Statistics
    Beta0.23Avg Volume744.60K
    52-Week High$80.9752-Week Low$26.91

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$77.85
    SMA 20$76.48
    SMA 50$73.14
    SMA 200$60.40
    EMA 10$76.93
    EMA 20$76.12
    EMA 50$72.94
    EMA 200$61.05

    MACD

    Line: 1.41Signal: 1.88Hist: -0.47

    ADX

    ADX: 33.0+DI: 17.8-DI: 20.1

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down12.0
    PSAR$80.53

    Bollinger Bands

    Upper Band$81.27
    Lower Band$71.70
    %B Position1251%(Upper)
    Band Width0.36

    RSI (14-Day)

    Neutral
    49.6

    Momentum Oscillators

    Stoch %K39.8
    Stoch %D54.2
    Williams %R-65.6
    ROC (10d)-2.5%
    Momentum-1.95
    CCI (20d)-69.0
    MFI (14d)49.3

    Volatility Measures

    ATR (14d)$3.21(4.3%)
    StdDev (20d)2.39
    Hist Vol43.0%(High)

    Volume Flow

    VWAP$74.47
    OBV29.1M
    AD Line9.6M
    CMF (20d)0.158

    Volume Metrics

    Avg Vol (20d)750.5K
    Vol Ratio1.1x
    VWMA (20d)$76.38

    Pivot Points

    R3$81.25
    R2$79.70
    R1$77.02
    Pivot Point$75.47
    S1$72.80
    S2$71.25
    S3$68.57

    Advanced Oscillators

    TSI11.47
    Ultimate Osc52.9
    KST80.69

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.16M$1.08M$2.32M$1.67M$0$52,000$567,000$43,000$0$529,000$1,000$9,000
    Cost of Revenue$3.92M$2.96M$3.07M$1.58M$0$0N/A$0$0$0$4,000$0
    Gross Profit$-2,768,000$-1,879,000$-748,000$89,000$0$52,000$567,000$43,000$0$529,000$1,000$9,000
    Operating Expenses$83.63M$64.51M$47.95M$51.22M$48.74M$42.26M$38.51M$28.34M$25.96M$23.00M$19.36M$14.05M
    R&D$54.66M$43.73M$29.96M$27.88M$31.33M$27.47M$26.80M$19.62M$18.47M$17.21M$16.34M$11.73M
    SG&A$28.98M$20.78M$17.99M$23.33M$17.41M$14.79M$11.71M$8.72M$7.49M$5.79M$3.02M$2.32M
    Operating Income$-86,401,000$-66,389,000$-48,700,000$-51,129,000$-48,741,000$-42,204,000$-38,049,000$-28,295,000$-25,853,000$-22,469,000$-19,359,000$-14,043,000
    Interest Income$7.33M$6.29M$7.44M$7.42M$7.32M$7.75M$6.25M$7.89M$6.94M$5.54M$2.80M$2.28M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-79,056,000$-60,202,000$-41,309,000$-43,808,000$-41,426,000$-34,452,000$-31,798,000$-20,405,000$-18,902,000$-16,934,000$-16,559,000$-11,768,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-79,056,000$-60,202,000$-41,309,000$-43,808,000$-41,426,000$-34,452,000$-31,798,000$-20,405,000$-18,902,000$-16,934,000$-16,559,000$-11,768,000
    EBITDA$-85,535,000$-65,649,000$-46,953,000$-50,612,000$-48,589,000$-42,175,000$-36,788,000$-29,858,000$-28,304,000$-24,673,000$-20,814,000$-15,131,000
    EBIT$-86,385,000$-66,490,000$-48,753,000$-51,229,000$-48,745,000$-42,199,000$-38,043,000$-28,297,000$-25,845,000$-22,478,000$-19,363,000$-14,051,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CGON

    News

    CG Oncology, Inc. $CGON Shares Purchased by Algert Global LLC

    Algert Global LLC significantly increased its stake in CG Oncology, Inc. (NASDAQ:CGON) by 140.9% in the second quarter, bringing its total to 46,690 shares valued at approximately $3.3 million. The article also details mixed insider activity, including a major director purchase and sales, and notes that institutional investors collectively own 26.56% of the company. Despite missing analyst EPS estimates for the last quarter, CG Oncology's revenue exceeded forecasts, and analysts maintain a "Moderate Buy" consensus rating with an $83.18 price target.

    MarketBeat•8/29/26•
    Neutral

    ADAR1 Capital Management LLC Invests $8.43 Million in CG Oncology, Inc. $CGON

    ADAR1 Capital Management LLC has acquired 118,664 shares of CG Oncology, Inc. (NASDAQ:CGON) for approximately $8.43 million, establishing a new position in the clinical-stage biopharmaceutical company. Despite this institutional investment and a "Moderate Buy" consensus rating from analysts, CG Oncology recently missed its quarterly earnings expectations. The company's stock opened at $78.95, near its 52-week high, with institutional investors collectively owning 26.56% of the shares.

    MarketBeat•8/26/26•
    Neutral

    Another California giant bolts for Texas as multi-billion-dollar company announces move

    CG Oncology, a $7 billion Nasdaq-traded biotech firm focused on bladder cancer treatments, has moved its corporate headquarters from Irvine, California, to Dallas, Texas. The company cited access to talent, investors, strategic partners, and cost advantages in Dallas's growing life sciences ecosystem. This move is part of a larger trend of companies, including major names like Tesla and Oracle, relocating from California due to high corporate taxes, regulations, and living costs.

    New York Post•8/26/26•
    Bullish

    CG Oncology (NASDAQ: CGON) officer eyes new sale after $7.9M August stock trade

    An officer at CG Oncology (NASDAQ: CGON), Ambaw Bellete, has filed a Form 144 indicating an intention to sell 10,551 shares of common stock on or about August 25, 2026, following a stock option exercise. This planned sale is valued at approximately $839,338.38. The filing also details numerous prior sales by Bellete in July and August 2026, including a significant transaction of 100,000 shares for over $7.9 million on August 19, 2026.

    Stock Titan•8/25/26•
    Somewhat-Bearish

    CG Oncology (NASDAQ: CGON) officer plans new sale after $7.95M August trade

    Ambaw Bellete, an officer at CG Oncology, Inc. (CGON), has filed a Form 144 notice indicating a proposed sale of 5,762 shares of common stock following a stock option exercise. This follows several significant sales by Bellete in the past three months, including transactions totaling $7.95 million on August 19, 2026, and $5.67 million on August 6, 2026. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ exchange.

    Stock Titan•8/24/26•
    Somewhat-Bearish

    Frequently Asked Questions About CGON

    Does CGON pay dividends?
    CG Oncology, Inc. Common stock (CGON) does not currently pay a regular dividend.
    What is CGON's market cap?
    CG Oncology, Inc. Common stock (CGON) has a market capitalization of $6.66B with a current stock price of $75.16.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In